Emyria delivers more than $2 million in clinical billings in the past half-year
Emyria Ltd (ASX:EMD), a mental health and neurologically focused biotechnology company developing a cutting-edge MDMA-assisted therapy model, has had a busy...
Source: proactiveinvestors.com.au